Cargando…

Molecular testing for adult type Alport syndrome

BACKGROUND: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pont-Kingdon, Genevieve, Sumner, Kelli, Gedge, Friederike, Miller, Chris, Denison, Joyce, Gregory, Martin, Lyon, Elaine
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780398/
https://www.ncbi.nlm.nih.gov/pubmed/19919694
http://dx.doi.org/10.1186/1471-2369-10-38
_version_ 1782174479399518208
author Pont-Kingdon, Genevieve
Sumner, Kelli
Gedge, Friederike
Miller, Chris
Denison, Joyce
Gregory, Martin
Lyon, Elaine
author_facet Pont-Kingdon, Genevieve
Sumner, Kelli
Gedge, Friederike
Miller, Chris
Denison, Joyce
Gregory, Martin
Lyon, Elaine
author_sort Pont-Kingdon, Genevieve
collection PubMed
description BACKGROUND: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in other families ESRD occurs in middle age. Few of the more than four hundred mutations described in COL4A5 are associated with adult type XLAS, but the families may be very large. METHODS: We classified adult type AS mutation by prevalence in the US and we developed a molecular assay using a set of hybridization probes that identify the three most common adult type XLAS mutations; C1564S, L1649R, and R1677Q. RESULTS: The test was validated on samples previously determined to contain one or none of these mutations. In the US, the test's clinical specificity and sensitivity are estimated to be higher than 99% and 75% respectively. Analytical specificity and sensitivity are above 99%. CONCLUSION: This test may be useful for presymptomatic and carrier testing in families with one of the mutations and in the diagnosis of unexplained hematuria or chronic kidney disease.
format Text
id pubmed-2780398
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27803982009-11-21 Molecular testing for adult type Alport syndrome Pont-Kingdon, Genevieve Sumner, Kelli Gedge, Friederike Miller, Chris Denison, Joyce Gregory, Martin Lyon, Elaine BMC Nephrol Technical Advance BACKGROUND: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in other families ESRD occurs in middle age. Few of the more than four hundred mutations described in COL4A5 are associated with adult type XLAS, but the families may be very large. METHODS: We classified adult type AS mutation by prevalence in the US and we developed a molecular assay using a set of hybridization probes that identify the three most common adult type XLAS mutations; C1564S, L1649R, and R1677Q. RESULTS: The test was validated on samples previously determined to contain one or none of these mutations. In the US, the test's clinical specificity and sensitivity are estimated to be higher than 99% and 75% respectively. Analytical specificity and sensitivity are above 99%. CONCLUSION: This test may be useful for presymptomatic and carrier testing in families with one of the mutations and in the diagnosis of unexplained hematuria or chronic kidney disease. BioMed Central 2009-11-17 /pmc/articles/PMC2780398/ /pubmed/19919694 http://dx.doi.org/10.1186/1471-2369-10-38 Text en Copyright ©2009 Pont-Kingdon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Technical Advance
Pont-Kingdon, Genevieve
Sumner, Kelli
Gedge, Friederike
Miller, Chris
Denison, Joyce
Gregory, Martin
Lyon, Elaine
Molecular testing for adult type Alport syndrome
title Molecular testing for adult type Alport syndrome
title_full Molecular testing for adult type Alport syndrome
title_fullStr Molecular testing for adult type Alport syndrome
title_full_unstemmed Molecular testing for adult type Alport syndrome
title_short Molecular testing for adult type Alport syndrome
title_sort molecular testing for adult type alport syndrome
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780398/
https://www.ncbi.nlm.nih.gov/pubmed/19919694
http://dx.doi.org/10.1186/1471-2369-10-38
work_keys_str_mv AT pontkingdongenevieve moleculartestingforadulttypealportsyndrome
AT sumnerkelli moleculartestingforadulttypealportsyndrome
AT gedgefriederike moleculartestingforadulttypealportsyndrome
AT millerchris moleculartestingforadulttypealportsyndrome
AT denisonjoyce moleculartestingforadulttypealportsyndrome
AT gregorymartin moleculartestingforadulttypealportsyndrome
AT lyonelaine moleculartestingforadulttypealportsyndrome